3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Neoplasms
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Interventions
Carboplatin
335
Pemetrexed
276
Cisplatin
228
Paclitaxel
193
pembrolizumab
178
Erlotinib Hydrochloride
173
Docetaxel
154
Gemcitabine
126
Nivolumab
112
Bevacizumab
112
Radiotherapy
84
Etoposide
68
durvalumab
62
atezolizumab
59
Ipilimumab
51
Radiosurgery
49
osimertinib
42
130-nm albumin-bound paclitaxel
40
Afatinib
39
Gefitinib
38
Cetuximab
38
Albumin-Bound Paclitaxel
37
Taxes
32
Vinorelbine
29
Radiation
29
Topotecan
28
Drug Therapy
25
Crizotinib
23
Platinum
21
Dexamethasone
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
pralsetinib
×
Thoracic
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA